Education
About Us
Working with TipRanks
Follow Us
Vaxart (VXRT)
:VXRT
VXRT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $0.98
Previous CloseN/A
Volume1.40M
Average Volume (3M)504.59K
Market Cap
$88.82M
Enterprise Value$95.97M
Total Cash (Recent Filing)$26.27M
Total Debt (Recent Filing)$16.11M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 13, 2025EPS Estimate
-0.07Last Dividend Ex-Date
Nov 09, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding228,919,070
10 Day Avg. Volume500,126
30 Day Avg. Volume504,591
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$4.00Price Target Upside925.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Vaxart News
VXRT FAQ
What was Vaxart’s price range in the past 12 months?
Vaxart lowest stock price was $0.26 and its highest was $0.98 in the past 12 months.
What is Vaxart’s market cap?
Vaxart’s market cap is $88.82M.
When is Vaxart’s upcoming earnings report date?
Vaxart’s upcoming earnings report date is Nov 13, 2025 which is in 56 days.
How were Vaxart’s earnings last quarter?
Vaxart released its earnings results on Aug 13, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.087 by $0.017.
Is Vaxart overvalued?
According to Wall Street analysts Vaxart’s price is currently Undervalued.
Does Vaxart pay dividends?
Vaxart pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart dividends here
What is Vaxart’s EPS estimate?
Vaxart’s EPS estimate is -0.07.
How many shares outstanding does Vaxart have?
Vaxart has 228,919,070 shares outstanding.
What happened to Vaxart’s price movement after its last earnings report?
Vaxart reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.087. Following the earnings report the stock price went down -2.703%.
Which hedge fund is a major shareholder of Vaxart?
Currently, no hedge funds are holding shares in VXRT
Vaxart Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (925.64% Upside)
$4.00 (925.64% Upside)
Hedge Fund Trend
Decreased
By 89.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $65.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.00%
12-Months-Change
Fundamentals
Return on Equity
-100.35%
Trailing 12-Months
Asset Growth
44.25%
Trailing 12-Months
Company Description
Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
VXRT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial growth and promising vaccine development results, but also addressed significant challenges such as the stop work order on a major trial and issues with stock listing compliance. Despite positive advancements in revenue and vaccine capabilities, the operational and financial uncertainties create a balanced sentiment.View all VXRT earnings summariesTechnical Analysis
MacroGenics
―
Immunic
―
Zentalis Pharmaceuticals
―
Orchestra BioMed Holdings
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
1.94% Insiders
5.54% Mutual Funds
0.44% Other Institutional Investors
92.08% Public Companies and
Individual Investors